Morning Briefing
Summaries of health policy coverage from major news organizations
Different Takes: Is Antibody Treatment Effective Against Omicron?; Should We Worry About A 'Twindemic'?
GlaxoSmithKline Plc has delivered some good news amid mounting concerns about the omicron variant. Its research showed that sotrovimab, the Covid-19 antibody treatment聽it developed with Vir Biotechnology Inc., is effective against the full combination of mutations seen in the new variant. Will this make it easier to live with omicron? Bloomberg Opinion鈥檚 Therese Raphael talks to Sam Fazeli,聽senior pharmaceutical analyst for聽Bloomberg Intelligence,聽about the development.聽(Therese Raphael and Sam Fazeli, 12/7)
Just before South African scientists identified the Omicron coronavirus variant, many experts were beginning to focus on a completely different potential problem: the collision of Covid-19 and influenza, which is now in the first weeks of its annual surge. If the issue seems familiar, it is because it is: there was a big fear last year over the possibility of the same unholy alliance. It was so concerning it was even dubbed the "twindemic," to denote the anticipated one-two punch of both viruses circulating at once. (Kent Sepkowitz, 12/7)
When I first heard President Biden announce that his administration will make rapid coronavirus tests free through insurance reimbursement, I thought it was a terrible plan. Why isn鈥檛 the government procuring tests directly and distributing them free of charge, rather than making Americans go through the onerous process of purchasing tests and then applying to insurance companies to get their money back? (Leana S. Wen, 12/7)
Recently, the U.S. Food and Drug Administration authorized COVID booster shots for all adults who have received their initial set of vaccinations. The CDC followed by strengthening their recommendation for all eligible people 18 years of age and older to get vaccinated. Most scientists knew when COVID-19 vaccines were first authorized that we would need at least one additional shot to complete the primary series, known as a prime-boost strategy. This is despite the vaccines鈥 outstanding initial efficacy. This sort of boost is required for many infectious disease vaccines to generate longer-lasting immunity. With holidays coming up, the emergence of new variants such as Omicron, and rising rates of infections in vaccinated individuals, it鈥檚 important to get boosters so we can move toward ending this pandemic. (Hayley A. Gans and Yvonne A. Maldonado, 12/7)
Covid-19 has brought on a behavioral health tsunami, a crisis in the brewing even before the pandemic. The effects on children鈥檚 health and mental health will be long-term. Children who have had Covid may become long haulers with both physical and behavioral health problems lasting years, or a lifetime. The solutions being sought must address both the immediacy of the crisis and the long-term needs. (Stephen Wanczyk-Karp, 12/8)
COVID-19 deaths nationwide will soon surpass 800,000. Too few will notice. 鈥淣ever in my wildest imagination did I think we would reach a point where a thousand-plus deaths a day would be normalized and met with a shrug,鈥 Alex Goldstein, founder of Faces of COVID, told me. I first spoke to him in mid-May 2020, two months into the virus鈥檚 initial wave. He had just posted his thousandth story to @FacesofCOVID on Twitter, tweet-sized remembrances of those killed by the disease caused by the coronavirus. (Renee Graham, 12/7)
Recently a patient in his 70s came seeking care at the small rural hospital in West Michigan where I鈥檝e worked as an emergency physician for two decades. He had tested positive for the coronavirus earlier in the week, was running a high fever and struggled to breathe. When asked if he鈥檇 been vaccinated, he snapped back, 鈥淚 don鈥檛 approve of the vaccine.鈥 (Dr. Rob Davidson, 12/8)